Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment has been dominated by chemotherapy followed by allo-SCT in eligible patients. However, following a flurry of drug approvals in 2017 and 2018, the AML treatment landscape is undergoing a transformation. The entry of novel agents into the treatment paradigm will enable the increasingly personalized treatment of patients, based on the characteristics of their disease and specific biomarkers. However, several areas of unmet need remain. Notably, patients unfit for intensive chemotherapy induction and relapsed/refractory AMLpatients offer significant commercial opportunity for innovative agents.
Label expansions and new drug approvals (e.g., FLT3 inhibitors, apoptosis-inducing agents) will fuel substantial growth of the AML therapy market over the 2017-2027 forecast period. This report provides insight on how treatment options for AML are likely to change over the 2017-2027 forecast period. It also analyzes the current and future earnings potential of AML therapies.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 17 country-specific interviews with thought leaders.
Epidemiology: Diagnosed incident cases of de novo AML and AML with MDS-related changes.
Population segments in market forecast: First-line AML, younger patients (aged < 60); first-line AML, older patients (aged ≥ 60); second-line AML, younger patients (aged < 60); second-line AML, older patients (aged ≥ 60); third-line AML.
Emerging therapies: Phase III: 11 drugs; Phase II: 27 drugs.
Already a Client? Log in to access this report.